Jazz Pharmaceuticals PLC $JAZZ Stock Position Lessened by Bessemer Group Inc.

Bessemer Group Inc. reduced its stake in shares of Jazz Pharmaceuticals PLC (NASDAQ:JAZZ – Free Report) by 12.7% during the third quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 19,550 shares of the specialty pharmaceutical company’s stock after selling 2,848 shares during the quarter. Bessemer Group Inc.’s holdings in Jazz Pharmaceuticals were worth $4,526,000 at the end of the most recent quarter.

Several other large investors have also recently modified their holdings of the stock. USA Financial Formulas purchased a new stake in shares of Jazz Pharmaceuticals during the first quarter valued at approximately $25,000. Pension & Wealth Management Advisors Inc. bought a new stake in Jazz Pharmaceuticals during the 3rd quarter valued at $32,000. Ameritas Advisory Services LLC bought a new stake in Jazz Pharmaceuticals in the 2nd quarter worth $47,000. Westpac Banking Corp bought a new stake in Jazz Pharmaceuticals in the 1st quarter worth $51,000. Finally, Elevation Wealth Partners LLC increased its position in shares of Jazz Pharmaceuticals by 156.4% in the third quarter. Elevation Wealth Partners LLC now owns 259 shares of the specialty pharmaceutical company’s stock valued at $60,000 after acquiring an additional 158 shares during the period. Hedge funds and other institutional investors own 89.14% of the company’s stock.

Jazz Pharmaceuticals Stock Down 2.6%

NASDAQ JAZZ opened at $230.40 on Friday. Jazz Pharmaceuticals PLC has a 52 week low of $156.95 and a 52 week high of $266.38. The company has a market capitalization of $14.79 billion, a P/E ratio of 21.26, a price-to-earnings-growth ratio of 0.43 and a beta of 0.38. The stock’s 50-day moving average price is $228.74 and its 200-day moving average price is $221.45. The company has a quick ratio of 1.64, a current ratio of 1.82 and a debt-to-equity ratio of 1.09.

Jazz Pharmaceuticals (NASDAQ:JAZZ – Get Free Report) last released its earnings results on Monday, November 2nd. The specialty pharmaceutical company reported ($3.88) earnings per share (EPS) for the quarter, topping the consensus estimate of ($4.03) by $0.15. Jazz Pharmaceuticals had a return on equity of 16.88% and a net margin of 4.37%. The firm had revenue of $1.24 billion during the quarter, compared to analysts’ expectations of $1.21 billion. During the same quarter last year, the business posted $8.13 earnings per share. The firm’s revenue was up 10.4% on a year-over-year basis. On average, equities research analysts predict that Jazz Pharmaceuticals PLC will post 11.18 earnings per share for the current year.

Insider Buying and Selling

In other news, EVP Neena M. Patil sold 1,200 shares of the business’s stock in a transaction dated Thursday, September 10th. The shares were sold at an average price of $240.94, for a total value of $289,128.00. Following the sale, the executive vice president directly owned 47,671 shares in the company, valued at $11,485,850.74. The trade was a 2.46% decrease in their position. The transaction was disclosed in a filing with the SEC, which is available at the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CAO Patricia Carr sold 1,413 shares of the company’s stock in a transaction that occurred on Wednesday, November 4th. The shares were sold at an average price of $231.36, for a total value of $326,911.68. Following the sale, the chief accounting officer owned 6,512 shares in the company, valued at approximately $1,506,616.32. This trade represents a 17.83% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Insiders sold 171,342 shares of company stock valued at $41,420,491 in the last ninety days. Company insiders own 4.10% of the company’s stock.

Wall Street Analyst Weigh In

A number of research analysts have issued reports on JAZZ shares. Canaccord Genuity Group set a $300.00 price objective on shares of Jazz Pharmaceuticals in a research report on Wednesday, August 26th. Truist Financial raised their target price on Jazz Pharmaceuticals from $281.00 to $286.00 and gave the company a “buy” rating in a research note on Wednesday, October 7th. Barclays upped their price target on Jazz Pharmaceuticals from $271.00 to $275.00 and gave the stock an “overweight” rating in a research note on Tuesday, November 3rd. JPMorgan Chase & Co. raised their price objective on Jazz Pharmaceuticals from $300.00 to $310.00 and gave the company an “overweight” rating in a research report on Tuesday, November 3rd. Finally, Morgan Stanley boosted their target price on shares of Jazz Pharmaceuticals from $319.00 to $324.00 and gave the company an “overweight” rating in a report on Friday, November 13th. One equities research analyst has rated the stock with a Strong Buy rating, seventeen have issued a Buy rating and two have assigned a Hold rating to the stock. Based on data from MarketBeat, Jazz Pharmaceuticals has a consensus rating of “Moderate Buy” and a consensus target price of $294.25.

Get Our Latest Stock Report on JAZZ

About Jazz Pharmaceuticals

(Free Report)

Jazz Pharmaceuticals plc is a global biopharmaceutical company focused on developing and commercializing medicines for serious diseases, particularly in neuroscience and oncology. Founded in 2003, the company is headquartered in Dublin, Ireland, and serves patients in the United States and international markets. Its products include treatments for sleep disorders and seizure conditions, such as Xywav, Xyrem, Sunosi and Epidiolex. Jazz also offers medicines used in cancer care, including Zepzelca, Vyxeos and Rylaze, as well as Defitelio for a serious complication following stem cell transplantation.

See Also

Want to see what other hedge funds are holding JAZZ? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Jazz Pharmaceuticals PLC (NASDAQ:JAZZ – Free Report).

Institutional Ownership by Quarter for Jazz Pharmaceuticals (NASDAQ:JAZZ)

Receive News & Ratings for Jazz Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Jazz Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.